Bae Sun Hwan
Department of Pediatrics, Konkuk University Medical Center, Seoul, Korea.
Korean J Pediatr. 2010 Jul;53(7):741-4. doi: 10.3345/kjp.2010.53.7.741. Epub 2010 Jul 31.
To evaluate the long-term safety of polyethylene glycol (PEG) 4000 in children with constipation, particularly the biochemical aspects of safety.
Medical records were evaluated, and 100 children, who had been taking PEG 4000 for more than 6 months, and who had been under clinical and biochemical monitoring, were enrolled. Ages; 6.11±3.12 years, Duration of therapy; 16.93±7.02 months, dose of PEG 4000; 0.72±0.21 g/kg/d.
None of the children complained of clinical adverse effect. The first biochemical test was performed at 8.05 months after beginning of PEG 4000. Serum phosphate (SP) value was high in 10 children, and leucopenia was noted in one child. The second test was performed in 44 children at 7.57 months after the first test. The SP value was high in four children, including the three children whose initial SP value was high and one new child. Six out of 10 children with high initial SP value became normal and one was lost. Hypernatremia was noted in one child. The third test was done in 15 children at 7.5 months after the second test. The SP value of the new child from the second test was high, but became normal after finishing treatment. Two out of 3 children with high SP value at the second test became normal and one was lost. The fourth test was done in 2 children few months after the third test. All of the results were normal. There were no relation between duration of therapy and hyperphosphatemia, or between dose of PEG 4000 and hyperphosphatemia.
PEG 4000 is safe for long-term therapy in children with constipation with respect to biochemical parameters.
评估聚乙二醇（PEG）4000用于便秘儿童的长期安全性，尤其是安全性的生化指标。
评估病历资料，纳入100名服用PEG 4000超过6个月且接受临床和生化监测的儿童。年龄：6.11±3.12岁，治疗时间：16.93±7.02个月，PEG 4000剂量：0.72±0.21 g/kg/d。
无儿童主诉临床不良反应。首次生化检测在开始服用PEG 4000后8.05个月进行。10名儿童血清磷酸盐（SP）值升高，1名儿童出现白细胞减少。首次检测后7.57个月对44名儿童进行了第二次检测。4名儿童SP值升高，包括最初SP值升高的3名儿童和1名新出现的儿童。最初SP值升高的10名儿童中有6名恢复正常，1名失访。1名儿童出现高钠血症。第二次检测后7.5个月对15名儿童进行了第三次检测。第二次检测中新出现的儿童SP值升高，但治疗结束后恢复正常。第二次检测时SP值升高的3名儿童中有2名恢复正常，1名失访。第三次检测后几个月对2名儿童进行了第四次检测。所有结果均正常。治疗时间与高磷血症之间、PEG 4000剂量与高磷血症之间均无关联。
就生化指标而言，PEG 4000用于便秘儿童的长期治疗是安全的。
